PD-L1 anticorps

N° du produit ABIN7608014

L’anticorps Human Chimeric anti-PD-L1 a été validé pour WB. Il convient pour détecter PD-L1 dans des échantillons de Humain.

Aperçu rapide pour PD-L1 anticorps (ABIN7608014)

Antigène: PD-L1 (CD274 (PD-L1))

Reactivité: Humain

Hôte: Human, Lapin

Clonalité: Chimeric

Conjugué: Cet anticorp PD-L1 est non-conjugé

Application: Western Blotting (WB)

Clone: 23D8

Détail du produit anti-PD-L1 anticorps

Fonction: Anti-PDL1 antibody(23D8), IgG1 Chimeric mAb

Purification: Purified from cell culture supernatant by affinity chromatography

Isotype: IgG1

Information d'application

Indications d'application: WB 1:1000

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

Stock: -20 °C,-80 °C

Stockage commentaire: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Date de péremption: 12 months

Détails sur PD-L1

Antigène: PD-L1 (CD274 (PD-L1))

Autre désignation: PDL1

Sujet: This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints